Dae Gyu Kim
Overview
Explore the profile of Dae Gyu Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
508
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim D, Kim M, Goo J, Kong J, Harmalkar D, Lu Q, et al.
Cell Chem Biol
. 2024 Sep;
31(11):1958-1968.e8.
PMID: 39260366
AIMP2-DX2 (hereafter DX2) is an oncogenic variant of aminoacyl-tRNA synthetase-interacting multifunctional protein 2 (AIMP2) that mediates tumorigenic interactions with various factors involved in cancer. Reducing the levels of DX2 can...
2.
Lee B, Kim D, Lee A, Kim Y, Cui L, Kim S, et al.
J Enzyme Inhib Med Chem
. 2022 Oct;
38(1):51-66.
PMID: 36305287
ARS-interacting multifunctional proteins 2 (AIMP2) is known to be a powerful tumour suppressor. However, the target AIMP2-DX2, AIMP2-lacking exon 2, is often detected in many cancer patients and cells. The...
3.
Lee B, Kim D, Kim Y, Kim S, Choi I
Bioorg Med Chem Lett
. 2022 Jul;
73:128889.
PMID: 35842206
Aminoacyl-tRNA synthetase (ARS) interacting multifunctional protein2 (AIMP2) plays a vital role in protein synthesis. However, a splicing variant in which the second of the four exons of AIMP2 is deleted,...
4.
Kim D, Choi Y, Lee Y, Lim S, Kong J, Song J, et al.
Nat Commun
. 2022 May;
13(1):2572.
PMID: 35546148
Recent development of the chemical inhibitors specific to oncogenic KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog) mutants revives much interest to control KRAS-driven cancers. Here, we report that AIMP2-DX2,...
5.
Kim D, Huddar S, Lim S, Kong J, Lee Y, Park C, et al.
J Pharmacol Exp Ther
. 2021 Sep;
379(3):358-371.
PMID: 34503993
Although protein-protein interactions (PPIs) have emerged as an attractive therapeutic target space, the identification of chemicals that effectively inhibit PPIs remains challenging. Here, we identified through library screening a chemical...
6.
Kim D, Park C, Huddar S, Lim S, Kim S, Lee S
Molecules
. 2020 Jun;
25(12).
PMID: 32549310
While aminoacyl-tRNA synthetase-interacting multifunctional protein 2 (AIMP2) is a tumor suppressor, its exon 2-depleted splice variant (AIMP2-DX2 or shortly DX2) is highly expressed in human lung cancer, and the ratio...
7.
Kim D, Nguyen T, Kwon N, Sung J, Lim S, Kang E, et al.
Biomolecules
. 2020 May;
10(6).
PMID: 32471182
AIMP2-DX2, an exon 2-deleted splice variant of AIMP2 (aminoacyl-tRNA synthetase-interacting multifunctional protein 2), is highly expressed in lung cancer and involved in tumor progression in vivo. Oncogenic function of AIMP2-DX2...
8.
Sivaraman A, Kim D, Bhattarai D, Kim M, Lee H, Lim S, et al.
J Med Chem
. 2020 Apr;
63(10):5139-5158.
PMID: 32315177
AIMP2-DX2, a splicing variant of AIMP2, is up-regulated in lung cancer, possesses oncogenic activity, and results in tumorigenesis. Specifically inhibiting the interaction between AIMP2-DX2 and HSP70 to suppress AIMP2-DX2-dependent cancers...
9.
Lee S, Kim D, Kim K, Kim T, Lim S, Kong H, et al.
J Med Chem
. 2020 Mar;
63(8):3908-3914.
PMID: 32208684
Aminoacyl-tRNA synthetase interacting multifunctional proteins (AIMPs) have recently been considered novel therapeutic targets in several cancers. In this publication we report the development of novel 2-aminophenylpyrimidines as new AIMP2-DX2 inhibitors....
10.
Lim S, Cho H, Kim D, Roh Y, Son S, Mushtaq A, et al.
Nat Chem Biol
. 2019 Dec;
16(1):31-41.
PMID: 31792442
A tumorigenic factor, AIMP2 lacking exon 2 (AIMP2-DX2), is often upregulated in many cancers. However, how its cellular level is determined is not understood. Here, we report heat-shock protein HSP70...